Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles
- PMID: 30577807
- PMCID: PMC6303985
- DOI: 10.1186/s12943-018-0923-9
Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles
Abstract
Right-sided colon cancer (RCC) has worse prognosis compared to left-sided colon cancer (LCC) and rectal cancer. The reason for this difference in outcomes is not well understood. We performed comparative somatic and proteomic analyses of RCC, LCC and rectal cancers to understand the unique molecular features of each tumor sub-types. Utilizing a novel in silico clonal evolution algorithm, we identified common tumor-initiating events involving APC, KRAS and TP53 genes in RCC, LCC and rectal cancers. However, the individual role-played by each event, their order in tumor development and selection of downstream somatic alterations were distinct in all three anatomical locations. Some similarities were noted between LCC and rectal cancer. Hotspot mutation analysis identified a nonsense mutation, APC R1450* specific to RCC. In addition, we discovered new significantly mutated genes at each tumor location, Further in silico proteomic analysis, developed by our group, found distinct central or hub proteins with unique interactomes among each location. Our study revealed significant differences between RCC, LCC and rectal cancers not only at somatic but also at proteomic level that may have therapeutic relevance in these highly complex and heterogeneous tumors.
Keywords: Clonal evolution; Hotspot mutations; Left-sided colon cancer; Proteomics; Rectal cancers; Right-sided colon cancer.
Conflict of interest statement
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
Ashiq Masood Advisory board and speaker Bureau Bristol-Myers Squibb and Boehringer Ingelheim, Honorarium Biocept. Janakiraman Subramanian Advisory board - Astra Zeneca, Pfizer, Boehringer Ingelheim, Alexion, Paradigm, Bristol-Myers Squibb Speakers Bureau - Astra Zeneca, Boehringer Ingelheim, Lilly Research Support - Biocept and Paradigm. Arif Hussain Advisory board – Novartis, Bayer, Astra Zeneca, Consultant – Bristol-Myers-Squibb. All other authors declare that they have no competing interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures



Similar articles
-
Different treatment strategies and molecular features between right-sided and left-sided colon cancers.World J Gastroenterol. 2015 Jun 7;21(21):6470-8. doi: 10.3748/wjg.v21.i21.6470. World J Gastroenterol. 2015. PMID: 26074686 Free PMC article. Review.
-
Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer.Sci Rep. 2017 Aug 11;7(1):7882. doi: 10.1038/s41598-017-08413-z. Sci Rep. 2017. PMID: 28801584 Free PMC article.
-
Comparative analyses of the prognosis, tumor immune microenvironment, and drug treatment response between left-sided and right-sided colon cancer by integrating scRNA-seq and bulk RNA-seq data.Aging (Albany NY). 2023 Jul 21;15(14):7098-7123. doi: 10.18632/aging.204894. Epub 2023 Jul 21. Aging (Albany NY). 2023. PMID: 37480572 Free PMC article.
-
Mechanisms of oncogenesis in colon versus rectal cancer.J Pathol. 2001 Sep;195(2):171-8. doi: 10.1002/path.918. J Pathol. 2001. PMID: 11592095
-
Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype.Expert Rev Anticancer Ther. 2018 Apr;18(4):351-358. doi: 10.1080/14737140.2018.1442217. Epub 2018 Feb 19. Expert Rev Anticancer Ther. 2018. PMID: 29458272 Review.
Cited by
-
Distinct microbes, metabolites, and the host genome define the multi-omics profiles in right-sided and left-sided colon cancer.Microbiome. 2024 Dec 28;12(1):274. doi: 10.1186/s40168-024-01987-7. Microbiome. 2024. PMID: 39731152 Free PMC article.
-
Heparanase modulates the prognosis and development of BRAF V600E-mutant colorectal cancer by regulating AKT/p27Kip1/Cyclin E2 pathway.Oncogenesis. 2022 Sep 21;11(1):58. doi: 10.1038/s41389-022-00428-0. Oncogenesis. 2022. PMID: 36130926 Free PMC article.
-
SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study.Front Oncol. 2022 Aug 1;12:939982. doi: 10.3389/fonc.2022.939982. eCollection 2022. Front Oncol. 2022. PMID: 35978833 Free PMC article.
-
[Clinical and histopathological characteristics of malignant colon tumors by location].Rev Med Inst Mex Seguro Soc. 2023 Sep 4;61(5):610-616. doi: 10.5281/zenodo.8316446. Rev Med Inst Mex Seguro Soc. 2023. PMID: 37769029 Free PMC article. Spanish.
-
Proteomic analysis of low- and high-grade human colon adenocarcinoma tissues and tissue-derived primary cell lines reveals unique biological functions of tumours and new protein biomarker candidates.Clin Proteomics. 2022 Jul 16;19(1):27. doi: 10.1186/s12014-022-09364-y. Clin Proteomics. 2022. PMID: 35842572 Free PMC article.
References
-
- Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) J Clin Oncol. 2014;32:LBA3. doi: 10.1200/jco.2014.32.18_suppl.lba3. - DOI
-
- Hong TS, Clark JW, Haigis KM. Cancers of the Colon and Rectum: identical or fraternal twins? Cancer Discov. 2012;2:117–121. doi: 10.1158/2159-8290.CD-11-0315. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous